Key facts
- Mythic Therapeutics’s last known valuation is $293.0M (Dec 2021).
- It has raised $156.5M across 4 recorded rounds; the latest was Early Stage VC ($29.9M) in Dec 2024.
- Notable investors include Viking Global Investors, BoxGroup, First Round Capital, Raptor Group, Venrock — 17 tracked in total.
- Mythic Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Dec 2024 ($29.9M sold to 30 investors).
- Status: Out of Business.
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Mythic Therapeutics
Funding rounds
4 roundsAbout Mythic Therapeutics
Developer of a biotechnology product platform designed to deliver chemotherapy directly to tumors through antibody-drug conjugates. The company's technology increases uptake in cancerous cells while avoiding payload release in normal cells, increases efficacy for a wide range of targets and cancer types without causing unacceptable side effects or toxicity, enabling medical practitioners to realize the full potential of patients, treat a broad array of tumor targets and leave a lasting impact on cancer care.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2017
- Employees
- 14
- Website
- mythictx.com/
- Ownership
- Out of Business
Mythic Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mythic Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mythic Therapeutics in its N-PORT filings yet. We sweep new filings monthly.